<code id='59852C371B'></code><style id='59852C371B'></style>
    • <acronym id='59852C371B'></acronym>
      <center id='59852C371B'><center id='59852C371B'><tfoot id='59852C371B'></tfoot></center><abbr id='59852C371B'><dir id='59852C371B'><tfoot id='59852C371B'></tfoot><noframes id='59852C371B'>

    • <optgroup id='59852C371B'><strike id='59852C371B'><sup id='59852C371B'></sup></strike><code id='59852C371B'></code></optgroup>
        1. <b id='59852C371B'><label id='59852C371B'><select id='59852C371B'><dt id='59852C371B'><span id='59852C371B'></span></dt></select></label></b><u id='59852C371B'></u>
          <i id='59852C371B'><strike id='59852C371B'><tt id='59852C371B'><pre id='59852C371B'></pre></tt></strike></i>

          entertainment

          entertainment

          author:leisure time    Page View:952
          Fiona Marshall, president of the Novartis research hub in Cambridge, Mass., speaks Thursday during the STAT Future Summit. STAT

          Swiss drugmaker Novartis’ research and development hub has a new name — and a new guiding strategy.

          The hub, which is headquartered in Cambridge, Mass., and for years has been known as Novartis Institutes for BioMedical Research, or NIBR, will soon simply be known as Novartis Biomedical Research.

          advertisement

          But that’s not the only thing that’s changing, Fiona Marshall, the hub’s president, told a virtual audience Thursday during the 2023 STAT Future Summit. The new name reflects a larger shift by the pharma giant to retool its research strategy — from one driven by the pure pursuit of scientific discovery to a tighter focus on projects likely to yield commercially successful drugs.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          AI models in health care face new federal disclosure requirements
          AI models in health care face new federal disclosure requirements

          AdobeFederalhealthtechnologyregulatorsonWednesdayfinalizednewrulestoforcesoftwarevendorstodiscloseho

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas